Short-term Response and Toxicity of Icotinib Hydrochloride in the Treatment for Advanced Non-small Cell Lung Cancer

[Purpose] To observe short-term response and toxicity of icotinib hydrochloride in the treatment for advanced non-small cell lung cancer(NSCLC).[Methods] Sixty-seven cases with NSCLC treated with icotinib hydrochloride alone taken orally for at least one month were enrolled in the study.Efficacy and toxicity were evaluated.[Results] Objective response rate(ORR)was 38.8%(26/67),and disease control rate(DCR)was 62.7%(42/67) in 67 cases,with complete response(CR),1 case;partial response(PR),25 cases;stable disease(SD),16 cases;and progressive disease(PD),25 cases.ORR and DCR were 59.5 %(22/37) and 73.0%(27/37) respectively in patients with CEA30μg/L,while those CEA30μg/L were 13.3%(4/30) and 46.7%(14/30) respectively,with significant difference between the two groups.The DCR of male was lower than that of female,and the DCR between genders showed significant difference after adjusting smoking status.Multivariate analysis showed that gender and CEA(30μg/L) were independent prognostic factors for short-term response.The major toxicities were skin rash(26.8%) and diarrhea(13.4%).[Conclusion] Monotherapy with icotinib hydrochloride is effective and tolerable for the patients with advanced NSCLC,especially for female patients or patients with CEA elevation.